A Study to Evaluate the Effect of Latanoprostene Bunod Ophthalmic Solution 0.024% on Episcleral Venous Pressure and Outflow Facility in Participants With Ocular Hypertension

Participation in any drug or device clinical investigation within 30 days prior to Visit 1 (Screening) or anticipation of participating in any other drug or device clinical investigation within the duration of this study.

Participants with a history or presence of chronic generalized systemic disease that the Investigator feels might increase the risk to the participant or confound the results of the study.

Female participants who are pregnant or breastfeeding.

Drug Therapies

Participants with an anticipated need to initiate or modify medication (systemic or topical) that is known to affect IOP (for example, steroids, α-adrenergic agonists, β-adrenergic antagonists, calcium channel blockers, angiotensin-converting enzyme \[ACE\] inhibitors, and angiotensin II receptor blockers).

Participants with known hypersensitivity or contraindications to latanoprostene bunod or any of the ingredients in the study drugs.

Diseases

Participants who are unable to discontinue contact lens use during and for 15 minutes following instillation of study drug and for 24 hours before check-in and during each study visit.

Participants with a central corneal thickness less than 480 μm or greater than 600 micrometer (μm) in either eye.

Participants with any condition that prevents reliable applanation tonometry (for example, significant corneal surface abnormalities) in either eye.

Participants who are monocular.

Participants with ocular conditions, which, in the opinion of the Investigator, will impact the study measurements, such as:

1. Active optic disc hemorrhage in either eye.

2. Current or a history of central/branch retinal vein or artery occlusion in either eye.

3. Current or a history of macular edema in either eye.

4. Very narrow angles (3 quadrants with less than Grade 2 according to Shaffer's anterior chamber angle grading system) and participants with angle closure, congenital, and secondary glaucoma, and with history of angle closure in either eye.

5. Diagnosis of a clinically significant or progressive retinal disease (for example, diabetic retinopathy, exudative or severe non-exudative macular degeneration) in either eye.

Participants with any intraocular infection or inflammation in either eye within 3 months prior to Visit 1 (Screening).

Myopia greater than -4.00 diopter (D), or hyperopia greater than +2.000

Surgery

Participants with a history of ocular laser surgery in either eye within the 3 months (90 days) prior to Visit 1 (Screening).

Participants with a history of laser trabeculoplasty, cyclophotocoagulation or glaucoma surgical procedures at any time prior to Visit 1 (Screening).

Participants with a history of incisional ocular surgery other than routine uncomplicated cataract surgery or severe trauma in either eye within the 3 months (90 days) prior to Visit 1 (Screening).

What this study is about